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| INTRODUCTION
Brain metastases are common in metastatic melanoma, with up to 20% of patients having such disease at diagnosis and up to 75% developing it over time. [1] [2] [3] Traditionally, melanoma patients with brain metastases have had a dismal prognosis, with a median overall survival of 4.7 months 2 and only 1.3 months for patients treated with immunosuppressive corticosteroids, 4 which are frequently required to control tumor-associated edema in the brain.
T-cell checkpoint immunotherapy, such as that with anti-CTLA-4
(cytotoxic T-lymphocyte-associated protein 4) and/or anti-PD-1 (programmed death 1) antibodies, has dramatically improved the prognosis of patients with metastatic melanoma. [5] [6] [7] As the mechanism of action of immunotherapy relies on robust immune responses, immunosuppression with corticosteroids may reduce the efficacy of this treatment, 8 although this has not been conclusively demonstrated.
Nonetheless, clinical trials of checkpoint inhibitors have typically excluded patients requiring more than 10 mg per day prednisolone equivalent. 7 Concerns regarding possibly reduced efficacy of immunotherapy, as well as adverse events associated with high-dose corticosteroids, motivate clinicians to minimize corticosteroid use in patients receiving immunotherapy. However, an increasingly common clinical dilemma arises in patients requiring steroids to control symptoms related to edema associated with brain metastases.
The mechanisms by which corticosteroids reduce vasogenic edema are not completely understood, 9 but may be mediated by VEGF (vascular endothelial growth factor). 10 On this basis, bevacizumab, an anti-VEGF monoclonal antibody, has been used to improve clinical symptoms and edema associated with cerebral radiation necrosis. 11 Interestingly, bevacizumab may be synergistic with ipilimumab against metastatic melanoma by augmenting immune cell infiltration of tumors. 12 Bevacizumab has not previously been evaluated as a means of improving symptoms in patients with edema surrounding brain metastases. Despite this, off-label bevacizumab has been used at our institution for this purpose in select patients with melanoma brain metastases, with the aim of minimizing steroid use and facilitating immunotherapy. Here, we present the outcomes for these patients.
| METHODS

| Patient identification and clinical data collection
The project was approved by Peter MacCallum Cancer Centre's Human Research and Ethics Committee. As this was a retrospective case series, the need for individual informed consent was waived. 
| Bevacizumab and immunotherapy treatment
Eight patients received 7.5 mg/kg intravenous bevacizumab every 3 weeks and four patients received 5 mg/kg every 2 weeks (Table 2 ). The median total number of bevacizumab treatments per patient was four (range 1-9). Two patients received only one dose of bevacizumab and were not evaluable for radiological or disease outcomes; one (P01) had very rapid disease progression and died within 2 weeks, while the other (P03) declined further active treatment ( Figure 1 ). Of the 10 evaluable patients, seven received ipilimumab and three received pembrolizumab after bevacizumab ( Figure 1 , 
| Corticosteroid treatment
Eight of the 10 evaluable patients required dexamethasone prior to commencement of bevacizumab and six of these were able to reduce their dexamethasone dose by more than 50% in the first 4 weeks after bevacizumab ( Table 2 ). In two others, bevacizumab was used instead of steroids to improve edema-associated symptoms and/or to minimize potential future steroid requirements. The patient who opted against further active treatment later started steroids to improve constitutional rather than neurological symptoms. No patients treated with greater than or equal to two doses of bevacizumab required increased steroids to control brain edema.
| Radiological findings
Prior to bevacizumab, all 12 patients had peritumoral edema surrounding brain metastases on imaging (Table 3) Table 3 ). One of these had increased hemorrhage in lesions, as well as a small asymptomatic subdural hematoma, but the surrounding edema decreased. Two patients had increased edema with progressive brain metastases. Brain metastases that were not hemorrhagic prior to bevacizumab did not become hemorrhagic after bevacizumab.
| Adverse events
Adverse events potentially related to bevacizumab are described in Table 4 . As above, one patient developed an asymptomatic thin subdural hematoma, which resolved without sequelae after ceasing bevacizumab. Another patient, who had received four doses of bevacizumab, had a sudden deterioration that was attributed to intracranial bleeding, although this could not be confirmed radiologically.
Two patients had gastrointestinal bleeding after bevacizumab in the setting of known small bowel metastases. One had had gastrointestinal bleeding before starting bevacizumab, requiring blood transfusions and palliative radiotherapy. This patient's post-bevacizumab bleeding event self-resolved and he received four more doses of 
| Disease course and symptomatic responses
The median survival of the entire 12-patient cohort from first dose of bevacizumab was 5.4 months (range 9 d to more than 4 y) (Figure 1 ).
The median survival from diagnosis of melanoma brain metastasis was in seven evaluable patients, were stable in two patients and worsened in one (Table 3) . Bevacizumab was used again successfully to treat headache, dysphasia, and radiological edema. At census, the patient remained well, with ongoing anti-PD-1 therapy more than 4 years after her initial course of bevacizumab and had avoided corticosteroid use during this time.
| DISCUSSION
Use of immunosuppressive high-dose corticosteroids to ameliorate symptoms related to malignant progression is clinically indicated in multiple contexts, and can be life-saving. However, this use needs to be carefully considered in the era of cancer immunotherapy, in which effective T-cell checkpoint inhibition can lead to durable and deep antitumor responses 5-7 against both intracranial and extracranial disease. 8 The CheckMate 204 and Australian ABC studies demonstrated intracranial response rates of 44% to 55% with combination of ipilimumab/nivolumab immunotherapy in patients with asymptomatic melanoma brain metastases, 14, 15 although response rates in symptomatic disease appear to be lower. 15 As a result of immunotherapy, cancer patients with previously very poor prognosis disease, such as brain metastases from melanoma, may now live many years. 6, 16 This highlights the importance of minimizing immunosuppression and maximizing opportunities for effective immunotherapy in every patient.
We have found that use of bevacizumab can be highly effective in the control of peritumoral edema from brain metastases in melanoma patients. It permits weaning of steroids while improving edema and symptoms, facilitating treatment with immunotherapy that can provide durable control of disease in otherwise very poor prognosis contexts. 4 Bevacizumab has previously and successfully been used to wean corticosteroids in patients with symptomatic cerebral radiation necrosis 11 and has been shown to improve radiological edema and clinical symptoms associated with radiation necrosis in melanoma brain metastases. 17 Our findings show that its use can be safely and efficaciously extended to patients with progressing, symptomatic, and edematous brain metastases, particularly when immunotherapy is planned.
Most patients in our series had heavily pretreated brain metastases, including surgical resections, radiotherapy, and previous systemic treatment. As such, they constituted a subset of patients with particularly poor prognosis and limited treatment options. Bevacizumab was used in these patients with the aim of reducing corticosteroid requirements and, thereby, maximizing the likelihood of tumor response to subsequent immunotherapy. Bevacizumab in combination with temsirolimus was associated with reduced circulating FoxP3+ regulatory T-cells compared with pretreatment samples. 18 The addition of bevacizumab to carboplatin and paclitaxel chemotherapy appeared to improve survival and response rates, but this was not statistically significant. 19 These studies were per- nonsmall cell lung cancer and asymptomatic brain metastases. 20 This study focused on patients with little or no edema related to their metastases, therefore limiting detection of a potential effect of bevacizumab in decreasing edema. 20 The REBECA study used bevacizumab in combination with whole brain radiotherapy for brain metastases from breast, lung, ovarian, or unknown primary tumors. 21 All patients were started on prophylactic steroids prior to treatment. 21 None of these studies assessed the efficacy of bevacizumab in reducing peritumoral edema and resultant symptoms, or in enabling steroid wean. However, they did conclude that bevacizumab could be safely used in patients with brain metastases.
Of particular concern in patients with brain metastases is the risk of tumor-associated bleeding, which may be promoted by bevacizumab due to poorly understood mechanisms that may include reduced renewal of endothelial cells and consequent compromise of blood vessel integrity. 22 In the BRAIN study, one patient (1%) had a grade 1 intracranial hemorrhage that resolved without sequelae. 20 In the REBECA trial, two of 19 patients (11%) had intralesional hemorrhage but no parenchymal brain hemorrhage. 21 In glioblastoma multiforme, bevacizumab was associated with a higher rate of intracranial hemorrhage than steroids alone (3.3% vs 2%). 23 Hemorrhage is of particular concern in melanoma brain metastases because of their high propensity for spontaneous hemorrhage. [24] [25] [26] Consistent with this, 10 of 12 patients in our series had brain metastases with imaging evidence of hemorrhage prior to treatment.
Despite this, and given the inherent tendency of melanoma metastases to bleed, no patients had radiologically confirmed worsening of intratumoral hemorrhage that could be specifically attributed to bevacizumab. However, it is difficult to exclude an effect of bevacizumab on hemorrhage risk given the above, so the risk of catastrophic hemorrhage should be discussed with patients ahead of treatment.
Gastrointestinal perforation may also complicate therapy with bevacizumab. 22 In our series, two patients with known small bowel metastases experienced gastrointestinal bleeding during bevacizumab treatment, including one receiving concurrent pembrolizumab complicated by a fatal bowel perforation. Although gastrointestinal metastases are common in patients with melanoma, spontaneous bleeding and perforation are not. 27 It is unknown whether immunotherapyassociated colitis might be more inclined to be complicated by perforation when treated concurrently with bevacizumab. Again, although gastrointestinal complications may occur spontaneously, the small but life-threatening risk of perforation should be discussed ahead of bevacizumab treatment in melanoma patients, particularly those with known bowel metastases or a history of enterocolitis.
The main limitations of our study are its small, retrospective, single-center nature, and our lack of a control comparator group. This is related to our off-label use of bevacizumab in this context, which 
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